Pacific Biosciences of California, Inc. (PACB)
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Related Infractions And The Schall Law Firm Urges Impacted Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.06, marking a -1.9% move from the previous day.
Reasons to Retain PacBio Stock in Your Portfolio for Now
PACB's strong product demand and continued focus on R&D raise optimism about the stock.
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Are Encouraged To Join An Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Impacted Shareholders To Help
LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Related Infractions And The Schall Law Firm Urges Impacted Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
